Replies to post #566892 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

A fact that NVCR C-level management knows well. HyGro knows it too.

[jondoeuk]

They could present data from this at ASCO https://www.businesswire.com/news/home/20230105005325/en/Novocure-Announces-Pivotal-LUNAR-Study-in-Non-Small-Cell-Lung-Cancer-Met-Primary-Overall-Survival-Endpoint

Should approval for second-line NSCLC come, which I think it will, the company is trying to shift the device to first-line, with checkpoint inhibitors. For that, they are working with MRK, running a single-arm PhII (KEYNOTE-B36). Data could come next year.

Also, over the next 18 months, data from multiple other pivotal trials, such in ovarian and pancreatic will read-out. In addition, more pivotal trials could start in HCC and ndGBM (again, working with MRK, so another KEYNOTE trial), and a number of combo trials, such as with RHHBY's Tecentriq in pancreatic, and another using BMY's Opdivo.

As for NWBO, nothing.